Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and GIP , could offer a significant step forward for obesity management . Early human trials have shown https://faydats542109.dailyblogzz.com/42012098/a-retatrutide-peptide-compound-a-breakthrough-in-body-control